---
title: "Ambrx Biopharma (AMAM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AMAM.US.md"
symbol: "AMAM.US"
name: "Ambrx Biopharma"
industry: "Biotechnology"
datetime: "2026-05-21T21:02:00.375Z"
locales:
  - [en](https://longbridge.com/en/quote/AMAM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AMAM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AMAM.US.md)
---

# Ambrx Biopharma (AMAM.US)

## Company Overview

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: D (0.65)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 357 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -27.82% |  |
| Net Profit YoY | 22.56% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 4093000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | -1638.31% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -27.82% | E |
| Net Profit YoY | 22.56% | B |
| Total Assets YoY | 0.00% | D |
| Net Assets YoY | 0.00% | D |
| Cash Flow Margin | -6.10% | D |
| OCF YoY | -27.82% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 10.72% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Ambrx Biopharma",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-27.82%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "22.56%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4093000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-1638.31%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-27.82%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "22.56%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-6.10%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-27.82%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "10.72%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 28.00 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AMAM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AMAM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AMAM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AMAM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**